Thyroid cancer is a malignant neoplasm arising from thyroid tissue, with major histologic subtypes including papillary, follicular, medullary, and anaplastic carcinoma. Most cases are differentiated cancers with generally favorable outcomes when detected early.
Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
A randomized trial found that remote telehealth genetic services increase uptake of genetic counseling and testing in adult survivors of childhood cancer. At six months, 43% of the telehealth group received services vs. 15% in usual care, with actionable results in 10% of those tested.
Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.
A real-world analysis found BRAF V600E-mutated papillary thyroid cancer had a proinflammatory molecular profile, but no significant overall survival difference versus BRAF wild-type disease. Treatment choice among BRAF/MEK inhibitors, tyrosine kinase inhibitors, and immunotherapy was not associated with significant survival differences.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Bariatric surgery procedures have fallen 46.4% since 2022 as prescriptions for semaglutide and tirzepatide rose to 24.17% of eligible adults by Q3 2025, though 75.8% of eligible patients still receive no treatment.
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
Phase 3 LIBRETTO-432 trial met its primary endpoint, showing selpercatinib delivered statistically significant and clinically meaningful improvement in event-free survival versus placebo as adjuvant therapy in early-stage RET fusion-positive NSCLC.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07777536 |
Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer |
RECRUITING | PHASE2 |
| NCT07753499 |
Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer |
RECRUITING | NA |
| NCT07752277 |
Quantitative Pharmacology-Based Dose Adjustment Protocol in Postoperative Thyroid Cancer Patients |
COMPLETED | |
| NCT07707401 |
Effectiveness of WeChat-Supported Neck Rehabilitation Exercises on Early Recovery After Thyroidectomy |
RECRUITING | NA |
| NCT07705074 |
FAPI PET Imaging - An Exploratory Study |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07704658 |
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors |
RECRUITING | PHASE4 |
| NCT07690839 |
Pre-Clinic Visit Online Education for Thyroid Cancer |
NOT_YET_RECRUITING | NA |
| NCT07654322 |
Clinical Study on the Efficacy of Laparoscopic Assisted Open Surgery Through Subclavian Approach for Unilateral Thyroid Cancer |
NOT_YET_RECRUITING | |
| NCT07634978 |
Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients |
RECRUITING | NA |
| NCT07623005 |
Progressive Muscle Relaxation for Pain and Quality of Life in Thyroid Cancer |
COMPLETED | NA |
